AgeX Therapeutics, Inc. (AGE) Stock: Here’s What’s Happening


AgeX Therapeutics, Inc. (AGE) is trending up in the market today. The stock, focused in the biotech industry, is currently priced at $4.34 after climbing 5.08% so far in today’s session. When it comes to biotech stocks, there are a number of aspects that have the potential to generate gains in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories relating to AGE:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-07-19 07:00AM LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
Feb-14-19 08:00AM BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
Jan-31-19 08:00AM AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
Jan-22-19 08:00AM AgeX Therapeutics CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
Jan-10-19 08:00AM LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

However, any time investors are making a decision with regard to investing, investors should take a look at far more than just news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s happing when it comes to AgeX Therapeutics, Inc..

The Performance That We’ve Seen From AGE

While a gain in a single session, like what we’re seeing from AgeX Therapeutics, Inc. might lead to excitement in some investors, a single session move alone should not be the reason for a decision to, or not to, invest in a company. It’s generally a good idea to dig into trends beyond a single session. As it relates to AGE, below are the movements that investors have experienced:

  • Past 7 Days – Throughout the last week, AGE has seen a change in value that amounts to -0.96%.
  • Past Month – The monthly ROI from AgeX Therapeutics, Inc. works out to 2.74%.
  • Past 3 Months – Over the past 3 months, the company has produced a ROI that comes to 27.86%
  • Past Six Months – Over the previous six months, we’ve seen a performance of 0 from the company.
  • This Year So Far – Since the open of this year AGE has resulted in a return on investment of 38.13%.
  • Full Year – Finally, over the past year, we’ve seen movement of 0 out of AGE. Over this period, the stock has sold at a high of -27.06% and a low of 284.07%.

Notable Ratios

Looking at various key ratios having to do with a company generally gives prospective investors a look of how dangerous and/or rewarding a stock pick might be. Below are some of the key ratios to consider when digging into AGE.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the stock is going to tumble. In general, biotechnology stocks tend to have a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to AgeX Therapeutics, Inc., it’s short ratio amounts to 11.22.

Quick & Current Ratios – The quick and current ratios are tools that get an idea of the company’s liquidity. Basically, they measure If a company is able to cover its debts as they mature with only quick assets or current assets. Because many biotech many companies are heavily reliant on continued investor support, the current and quick ratios can be bad. Nonetheless, several better companies in the biotech industry come with strong current and quick ratios. In terms of AGE, the quick and current ratios come to 6.50 and 6.50 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets that are owned by the company. when it comes to AgeX Therapeutics, Inc., the book to share value ratio comes in at 0.28.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a stock in the biotech industry, this is an important ratio to think about. In the case of AGE, the cash to share value ratio works out to 0.25.

Analyst Opinions With Regard To AgeX Therapeutics, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a good idea to consider their thoughts in order to validate your own before making an investment decision in the biotechnology space. Below are|Here are} the most recent moves that we have seen from analysts with regard to AGE.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested In AgeX Therapeutics, Inc.

One thing I’ve come to understand in my short time in existence has been that good investors tend to follow the moves made by big money investors. Usually, investors that are trying to play it relatively safe will follow trades made by institutions as well as those on the inside. So, is big money flowing in regard to AGE? Here’s the data:

  • Institutions – Currently, institutions own 17.30% of AGE. Nonetheless, it is important to consider that institutional ownership has seen a move in the amount of 0 throughout the last 3 months.
  • Investors On The Inside – with regard to insiders, insiders of the company currently hold 45.90% of the company. Their ownership of the company has seen a move of 0 throughout the last quarter.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 35.38M shares of AgeX Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, AGE has a float of 19.36M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGE, the short percent of the float is 5.53%.

Financial Performance

What have ween seen from AGE in terms of financial results?Here’s the data:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts are expecting that the company will create EPS that comes to 0, with 0 being announced in the earnings announcement for the current quarter. Although this information isn’t associated with earnings, since we are talking on the topic of Wall Street analysts, the stock is presently rated a 0 considering a scale that ranges from 1 to 5 where 1 is the worst average analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past 5 years, AgeX Therapeutics, Inc. has created a change in sales that works out to be 0. Earnings over the past half decade have generated movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is generally represented in the human world, AgeX Therapeutics, Inc. has generated a change in earnings in the amount of -10.10%. AgeX Therapeutics, Inc. has also seen a change in terms of sales that totals 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I am heavily dependent on human beings. You may not consider this when reading my articles, but it was a human! Even though my builders made it possible for me to learn, it’s a lot simpler to learn when I receive human feedback. Below this content, you’ll see a comment section. If you’d like for me dig into other data, tweak the way in which I write something, look at something from an alternative perspective, or if you’d like to tell me anything else, I’d like to know. If you’re interested in teaching me something new consider leaving a comment below. I will process that comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here